Skip to main content
. 2022 Aug 25;10(9):1389. doi: 10.3390/vaccines10091389

Figure 4.

Figure 4

Protein–protein docking results of vaccine construct with TLR-2 (a), TLR-4 (b), MHC class I (c) and MHC class II (d).